Eton Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Biorphen (phenylephrine hydrochloride) / Eton Pharma
2022-001023-32: The effect of catecholamines on intraoperative hemodynamics

Not yet recruiting
4
225
Europe
Suprarenin, Noradrenalin Orpha, Biorphen, Epinephrine, Norepinephrine, Phenylephrin, Solution for infusion, Suprarenin, Noradrenalin Orpha, Biorphen
Medical University of Vienna, Department of Anesthesia, General Intensive Care and Pain Medicine
Patients > 45 years of age at-risk for cardiovascular complications undergoing moderate- to high-risk major open abdominal surgery., Elderly patients undergoing major abdominal surgery, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
zonisamide oral suspension (ET-104) / Eton Pharma, Azurity Pharma
NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Not yet recruiting
4
40
US
Zonisamide Oral Product, ZONISADE, Zonisamide oral suspension
Azurity Pharmaceuticals
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
09/26
09/26
Increlex (mecasermin) / Eton Pharma
2012-001239-30: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. DE EFFECTEN VAN RECOMBINANTE HUMANE IGF-I OP DE VOEDINGSTOESTAND VAN LEVERCIRROSE PATIENTEN: EEN PILOT STUDIE.

Ongoing
4
6
Europe
Solution for injection, INCRELEX
Foundation for Liver Research, Foundation for Liver Research
Liver cirrhosis Levercirrose, Replacement of normal liver tissue by fibrosis, scar tissue leading to the loss of liver function. Vervanging van normale lever weefsel door fibrose, litteken weefsel waardoor de lever zijn functie verliest., Diseases [C] - Digestive System Diseases [C06]
 
 
2010-019737-94: ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA

Ongoing
4
20
Europe
-, INCRELEX 10 mg/ml solución inyectable., INCRELEX 10 mg/ml solución inyectable.
FIBHULP
Ataxia cerebelosa degenerativa de grado leve a moderado
 
 
2011-004104-38: ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA DE FRIEDREICH

Ongoing
3
30
Europe
INCRELEX 10 mg/ml solución inyectable, INCRELEX 10 mg/ml solución inyectable
FIBHULP, Ministerio de Sanidad, Política Social e Igualdad
Pacientes con ataxia de Friedreich
 
 
2010-022215-19: Combined growth hormone and IGF1 therapy in paediatric Crohn'd disease

Terminated
2
24
Europe
Increlex 10mg/ml solution for injection, NutropinAq 10mg/2ml solution for injection, Solution for injection, Increlex, NutropinAq®
Greater Glasgow & Clyde NHS
Impaired growth in Paediatric Crohn's disease, Impaired growth in Paediatric Crohn's disease, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT01970345: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Terminated
2
3
US
IGF-1, Increlex, mecasermin, Placebo/saline, Saline
Icahn School of Medicine at Mount Sinai, Autism Science Foundation
Autism Spectrum Disorder
09/17
09/17
NCT02636270: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Completed
1/2
7
NA
Increlex, rhIGF-1
Children's Hospital Medical Center, Cincinnati
Short Stature
10/22
12/22
EuIGFD, NCT00903110: Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Checkmark Observational data
Aug 2012 - Aug 2012: Observational data
Recruiting
N/A
500
Europe, US, RoW
Increlex®
Ipsen
IGF1 Deficiency
12/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Biorphen (phenylephrine hydrochloride) / Eton Pharma
2022-001023-32: The effect of catecholamines on intraoperative hemodynamics

Not yet recruiting
4
225
Europe
Suprarenin, Noradrenalin Orpha, Biorphen, Epinephrine, Norepinephrine, Phenylephrin, Solution for infusion, Suprarenin, Noradrenalin Orpha, Biorphen
Medical University of Vienna, Department of Anesthesia, General Intensive Care and Pain Medicine
Patients > 45 years of age at-risk for cardiovascular complications undergoing moderate- to high-risk major open abdominal surgery., Elderly patients undergoing major abdominal surgery, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
zonisamide oral suspension (ET-104) / Eton Pharma, Azurity Pharma
NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Not yet recruiting
4
40
US
Zonisamide Oral Product, ZONISADE, Zonisamide oral suspension
Azurity Pharmaceuticals
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
09/26
09/26
Increlex (mecasermin) / Eton Pharma
2012-001239-30: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. DE EFFECTEN VAN RECOMBINANTE HUMANE IGF-I OP DE VOEDINGSTOESTAND VAN LEVERCIRROSE PATIENTEN: EEN PILOT STUDIE.

Ongoing
4
6
Europe
Solution for injection, INCRELEX
Foundation for Liver Research, Foundation for Liver Research
Liver cirrhosis Levercirrose, Replacement of normal liver tissue by fibrosis, scar tissue leading to the loss of liver function. Vervanging van normale lever weefsel door fibrose, litteken weefsel waardoor de lever zijn functie verliest., Diseases [C] - Digestive System Diseases [C06]
 
 
2010-019737-94: ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA

Ongoing
4
20
Europe
-, INCRELEX 10 mg/ml solución inyectable., INCRELEX 10 mg/ml solución inyectable.
FIBHULP
Ataxia cerebelosa degenerativa de grado leve a moderado
 
 
2011-004104-38: ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA DE FRIEDREICH

Ongoing
3
30
Europe
INCRELEX 10 mg/ml solución inyectable, INCRELEX 10 mg/ml solución inyectable
FIBHULP, Ministerio de Sanidad, Política Social e Igualdad
Pacientes con ataxia de Friedreich
 
 
2010-022215-19: Combined growth hormone and IGF1 therapy in paediatric Crohn'd disease

Terminated
2
24
Europe
Increlex 10mg/ml solution for injection, NutropinAq 10mg/2ml solution for injection, Solution for injection, Increlex, NutropinAq®
Greater Glasgow & Clyde NHS
Impaired growth in Paediatric Crohn's disease, Impaired growth in Paediatric Crohn's disease, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT01970345: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Terminated
2
3
US
IGF-1, Increlex, mecasermin, Placebo/saline, Saline
Icahn School of Medicine at Mount Sinai, Autism Science Foundation
Autism Spectrum Disorder
09/17
09/17
NCT02636270: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Completed
1/2
7
NA
Increlex, rhIGF-1
Children's Hospital Medical Center, Cincinnati
Short Stature
10/22
12/22
EuIGFD, NCT00903110: Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Checkmark Observational data
Aug 2012 - Aug 2012: Observational data
Recruiting
N/A
500
Europe, US, RoW
Increlex®
Ipsen
IGF1 Deficiency
12/27
12/27

Download Options